Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEISH-F3 + GLA-SE
- Development stage
- Phase 1
- Lead developer
- Access to Advanced Health Institute
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LEISH-F3 + GLA-SE is a vaccine candidate developed for the prevention and treatment of visceral leishmaniasis (VL), a potentially fatal parasitic disease transmitted by sand flies. This vaccine combines recombinant Leishmania proteins with a powerful adjuvant to stimulate immune responses against the parasite. LEISH-F3 + GLA-SE is a recombinant vaccine candidate for the prevention and treatment of visceral leishmaniasis. It consists of the LEISH-F3 fusion protein (containing Leishmania infantum/donovani nonspecific nucleoside hydrolase and Leishmania infantum sterol 24-c-methyltransferase) combined with the GLA-SE adjuvant (glucopyranosyl lipid A formulated as stable emulsion). The vaccine stimulates both humoral and cell-mediated immune responses against Leishmania parasites.
- Other names
- LEISHMANIA NUCLEOSIDE HYDROLASE-STEROL 24-C-METHYLTRANSFERASE FUSION PROTEIN
02
Targets
Leish-F3 (Leishmania nucleoside hydrolase and sterol 24-c-methyltransferase)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on LEISH-F3 + GLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEISH-F3 + GLA-SE.